Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CES1 | P23141 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10793693 | 0.98 | CA2 (0.52) | CA2FAAHCES1CES2 | |
| SCHEMBL12287867 | 0.83 | — | — | |
| SCHEMBL9941 | 0.77 | CA2 (0.64) | CA2FAAHCES1CES2 | |
| SCHEMBL350042 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 | |
| SCHEMBL5586100 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 | |
| Fluoride SCHEMBL25435314 | 0.75 | CA2 (0.61) | CA2FAAHCES1CES2 | |
| SCHEMBL8778750 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 | |
| SCHEMBL8778833 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 | |
| SCHEMBL395321 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 | |
| SCHEMBL11058951 | 0.75 | CA2 (0.68) | CA2FAAHCES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
| EP-2032555-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | Novartis AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144127-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | CA2 1748/4885FAAH 4393/4885CES1 1825/4885 |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | CA2 2254/4885FAAH 1026/4885CES1 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.